InduPro raises $77M Series B, doses first patient in Phase 1 trial of IDP-001 targeting tumor protein pairs

InduPro raised $77 million in Series B financing and has dosed the first patient in a Phase 1 trial of IDP-001, an antibody-drug conjugate that uses the company’s ARRIS platform to target cancer cells by bringing two surface proteins together.